Login to Your Account



Amgen taps Cytomx Therapeutics in potential $1.47B bispecific deal

By Michael Fitzhugh
Staff Writer

Wednesday, October 4, 2017

Amgen Inc. agreed to pay $40 million up front and as much as $455 million in milestones to access as many as four T-cell engaging bispecific antibodies developed by Cytomx Therapeutics Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription